Tesamorelina
Stabilized GHRH analogue
GHRH analogue approved to reduce visceral fat in HIV lipodystrophy.
Back to technical sheets- Class
- Stabilized GHRH analogue
- Also known as
- Approved as tesamorelin (e.g. Egrifta®) for a specific indication
Mechanism of action
Stabilized GHRH analogue that stimulates endogenous GH secretion, reducing abdominal visceral fat.
Evidence
Clinical evidence
Clinical evidence: FDA-approved to reduce excess abdominal fat in HIV-associated lipodystrophy, with controlled trials.
Studied uses
- HIV-associated lipodystrophy (visceral fat reduction)
Safety considerations
- Raises IGF-1: oncologic precautions and monitoring
- Do not use in pregnancy or with active malignancy
- Injection-site reactions
Batch quality data
We publish these figures because they are the ones the program itself teaches you to ask for.
- Presentation
- Polvo liofilizado en vial sellado
10 mg MX$2,700 per vial
Educational reference sheet. It is not a recommendation to use, a clinical indication or a protocol. Many of these compounds are marketed for research use only and are not approved for human use. Always cross-check with the primary literature and the regulation in your country.